Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Serstech AB (SERT.ST)
Lund, SE
Founded in 2006 and headquartered in Lund, Sweden, Serstech AB is a global provider of advanced chemical identification instruments. The company's offerings include the compact, lightweight, handheld Serstech 100 Indicator, a Raman spectrometer capable of detecting a wide array of chemicals such as explosives, narcotics, toxic industrial chemicals, pharmaceuticals, and chemical warfare agents. Complementing its hardware, Serstech provides ChemDash, a centralized software platform for managing its devices. Furthermore, the product lineup features the innovative Serstech Arx and Arx+ for rapid and precise chemical substance identification, along with the Serstech SERS kit, designed for the quick detection of low-concentration substances and narcotics samples. These solutions are utilized across various critical applications, including explosives detection, CBRN (chemical, biological, radiological, nuclear) and hazmat response, narcotics analysis, and pharmaceutical quality control.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.62% | +7.43% | +56.22% | +12.02% | -13.99% | +3.03% | -27.11% | +66.09% | -73.85% | -17.80% | -74.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%-26.2% Q1'26: -67.2% (vs Q1'25)
-
EPS growth Chemicals: +11.7%-200.0% Q1'26: -407.8% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%-77.4% Q1'26: -107.6% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%-74.9% Q1'26: -103.2% (vs Q1'25)
-
ROIC Chemicals: +3.4%-76.1% Q1'26: -66.6% (vs Q1'25)
-
Share dilution Chemicals: +0.0%+11.3% Q1'26: +0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×0.00× Q1'26: 0.00× (vs Q1'25)
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|
| Revenue |
52.26M
est: 60.30M (-13.3%)
|
38.60M
est: 44.70M (-13.7%)
|
72.50M
72.50M – 72.50M
+62.2% YoY
|
103.80M
103.80M – 103.80M
+43.2% YoY
|
129.70M
129.70M – 129.70M
+25.0% YoY
|
| EBITDA |
-8.78M
est: -24.34M (+63.9%)
|
-20.59M
est: -18.05M (-14.1%)
|
-29.27M
-29.27M – -29.27M
-62.2% YoY
|
-41.91M
-41.91M – -41.91M
-43.2% YoY
|
-52.36M
-52.36M – -52.36M
-25.0% YoY
|
| EBIT |
-8.94M
est: -29.50M (+69.7%)
|
-28.92M
est: -21.87M (-32.3%)
|
-35.47M
-35.47M – -35.47M
-62.2% YoY
|
-50.78M
-50.78M – -50.78M
-43.2% YoY
|
-63.46M
-63.46M – -63.46M
-25.0% YoY
|
| Net Income |
-9.13M
est: 15.24M (-159.9%)
|
-29.27M
est: 38.10M (-176.8%)
|
58.43M
58.43M – 58.43M
+53.3% YoY
|
60.97M
60.97M – 60.97M
+4.3% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
—
est: 25.68M (-100.0%)
|
—
est: 19.04M (-100.0%)
|
30.88M
30.88M – 30.88M
+62.2% YoY
|
44.21M
44.21M – 44.21M
+43.2% YoY
|
55.24M
55.24M – 55.24M
+25.0% YoY
|
| EPS |
-0.04
est: 0.06 (-166.7%)
|
-0.12
est: 0.15 (-180.0%)
|
0.23
0.23 – 0.23
+53.3% YoY
|
0.24
0.24 – 0.24
+4.3% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Niclas Ekstrom | Chief Commercial Officer | — | male |
| Simon Persson | Chief Financial Officer | — | male |
| Stefan Sandor | MD & Chief Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SERT.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
